MEDICAL WEIGHT MANAGEMENT · SINGAPORE

Switching Between Tirzepatide and Semaglutide

There is no exact dose conversion between the two weekly GLP-1 injections. Here is why, what the head-to-head SURMOUNT-5 trial found, and how a doctor times and doses a safe switch.

Struggling with weight loss for years?
Get a doctor-prescribed solution to regulate appetite and supports sustainable weight loss by addressing hormonal and metabolic factors.

-20.2%

Tirzepatide in SURMOUNT-5 (3)

-13.7%

Semaglutide in SURMOUNT-5 (3)

7 Days

Usual gap from last to first dose (6)

💡

A note on terminology

This page uses tirzepatide and semaglutide, the generic names, rather than brand names, in line with Singapore's medical advertising guidelines, which restrict reference to registered trade names.

Where each medicine stands in Singapore

Before thinking about a switch, it helps to know what each weekly injection is registered for here.

✓ Semaglutide — Registered for weight management. The 2.4 mg weekly injection is registered for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. (5)

✓ Tirzepatide — Registered for type 2 diabetes. Tirzepatide was first registered to improve blood sugar control in adults with type 2 diabetes. (5)

✓ Tirzepatide — Registered for weight management. It has since been registered for chronic weight management in adults, under similar criteria to semaglutide. (5)

▸ Switching — No official conversion. Neither manufacturer publishes a dose conversion chart between the two, so any switch should be planned by a doctor. (6)

Why the doses don't convert

Semaglutide copies one gut hormone, GLP-1. Tirzepatide acts on two: GLP-1 and GIP, a second hormone that also affects appetite and how the body handles sugar and fat. (1) (2)

The two also come in very different strengths. Semaglutide steps up from 0.25 mg to 2.4 mg a week, while tirzepatide steps up from 2.5 mg to as much as 15 mg a week. (6)

So a milligram of one does not do the same job as a milligram of the other. Conversion tables found online are estimates. A starting dose should be set by a doctor who knows your history.

Fig. 1 — Semaglutide acts on the GLP-1 receptor; tirzepatide acts on both GLP-1 and GIP receptors.
Fig. 1 — Semaglutide acts on one receptor; tirzepatide acts on two.
Fig. 2 — Weekly dose steps: semaglutide 0.25 to 2.4 mg, tirzepatide 2.5 to 15 mg.
Fig. 2 — The weekly dose steps for each medicine.

What the trials found

Each medicine has its own large weight-management trial, shown below. A newer trial, SURMOUNT-5, then compared the two directly. (1) (2) (3)

Trial

Population (n)

Medicine, top dose

Weight change vs placebo

Duration

STEP 1

1,961 · obesity or overweight

Semaglutide 2.4 mg

-14.9% vs -2.4%

68 weeks

SURMOUNT-1

2,539 · obesity or overweight

Tirzepatide 15 mg

-20.9% vs -3.1%

72 weeks

SURMOUNT-5: head to head

In adults with obesity and no diabetes, people on tirzepatide lost an average of 20.2% of their body weight over 72 weeks, compared with 13.7% on semaglutide. Each person took the highest dose they could tolerate. (3)

Averages hide a wide range

A head-to-head trial in people with type 2 diabetes (SURPASS-2) showed a similar pattern. Even so, some people do very well on semaglutide, and some find tirzepatide harder to tolerate. The right medicine is the one that works for you and suits your other health conditions. (4)

Fig. 3 — SURMOUNT-5 average weight change at week 72: tirzepatide 20.2%, semaglutide 13.7%.
Fig. 3 — Average change in body weight at week 72. Source: SURMOUNT-5 (3).
Common reasons to switch

People move between the two medicines for many reasons, including:

  • Side effects that don't settle
  • Weight loss that has plateaued
  • Another health condition that favours one medicine
  • Supply of particular pen strengths
  • Cost or access
  • Personal preference for the pen or routine

A switch is not a failure. Responses to GLP-1 medicines vary from person to person, and changing treatment is a normal part of finding what works.

Whatever the reason, plan the switch with your doctor. Don't switch on your own with leftover pens or medicine from friends, family or online sellers.

What to expect after switching

Nausea or reflux can return briefly at the start and after each dose increase. Appetite may feel different for a few weeks, and weight loss may pause before settling again. Stopping treatment altogether, rather than switching, usually leads to weight regain. (7) (8) (9)

How a doctor plans the switch

Both medicines are taken once a week. In most cases, the new medicine starts on the day the next dose of the old one would have been due, about seven days after the last injection. The two are never used in the same week. (6)

The starting dose depends on your current dose, how well you tolerated it, how long ago your last injection was, your progress so far and your other medicines. Many doctors start at a lower or middle step rather than the top dose, then adjust.

If several weeks have passed since the last dose, appetite and tolerance may have reset, so the new medicine is usually restarted low.

A review a few weeks after switching lets your doctor check side effects, appetite and weight, and decide whether to move up a step.

Fig. 4 — A typical switch: last dose, about 7 days, first new dose, then a review.
Fig. 4 — A typical switch, from the last dose to the first review.

Tolerability when switching

In SURMOUNT-5, side effects were mostly gastrointestinal and broadly similar between the two medicines, and most were mild to moderate. They are most likely in the first weeks on a new medicine and after each dose increase. (3)

Commonly reported effects

  • Nausea
  • Diarrhoea
  • Constipation
  • Vomiting
  • Reflux or indigestion
  • Injection-site reactions
Book a Consultation & Check Your Eligibility
Weight loss can sometimes feel overwhelming and challenging. However, you do not have to face it alone. With the right treatment plan and professional guidance, you can achieve sustainable weight loss and reclaim your health with confidence.

Schedule a consultation with us today for a comprehensive body analysis and personalised treatment plan.
BOOK A CONSULTATION
Frequently asked questions
References

Studies and sources cited in this document

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
  3. Aronne LJ, Horn DB, le Roux CW, et al., for the SURMOUNT-5 Trial Investigators. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025.
  4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
  5. Health Sciences Authority, Singapore. Register of Therapeutic Products: semaglutide and tirzepatide. Checked November 2026.
  6. Singapore product information for semaglutide 2.4 mg and tirzepatide injections: dosing, dose escalation and missed-dose guidance.
  7. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564.
  8. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
  9. Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. 2021;325:1414-1425.

Detect any underlying health conditions.

When was the last time you had your full medical check up? Take charge of your own health – Begin with a comprehensive full body medical check-up and speak to your doctor.

Please indicate your current problem or share any other remarks for us to note before your appointment.

Take charge of your health today.

Your submission has been received.
Your submission has been received. Our customer representative will contact you soon! For quicker response, please call us at +65 8129 8877
Oops! Something went wrong while submitting the form.